Minnesota-based Urologix, Inc. is a market leader of minimally invasive medical products for both the relief and treatment of the symptoms and obstructions caused by Benign Prostatic Hyperplasia (BPH). Founded in 1991, the company currently develops, markets, manufactures, and distributes urological products that provide lasting relief for symptoms due to BPH.
Yesterday, Urologix announced that it has reached a significant milestone in its licensing agreement with Medtronic. Through this agreement Urologixwill now manufacture the Prostiva RF Therapy System, a registered trademark of Medtronic. The agreement allows for the rights to sell all Prostiva RF Therapy products under the Urologix brand nationwide. Working directly with Prostiva’s manufacturing partners, Urologix will reinforce quality and standards of excellence.
Intermixing the Prostiva® RF Therapy System alongside the innovative Urologix’ Cooled ThermoTherapy™, Urologix is now the company behind two leading in-office BPH technologies. The Prostiva® RF Therapy System reduces prostate tissue to help relieve overall BPH symptoms. The Urologix Cooled ThermoTherapy™ enhances patient comfort by means of a cooling mechanism that helps to protect the surrounding healthy tissue. Both systems help to provide safe revilement of the symptoms or obstructions caused by BPH. The Cooled ThermoTherapy™ family also includes Urologixproducts such as Targis®, CoolWave®, the CTC Advance®, and the Targis® catheter families.
For more information, please visit www.urologix.com
Let us hear your thoughts below: